Please login to the form below

Benicar

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Benicar was produced by Daiichi Sankyo.

Daiichi Sankyo to shut down German antibody unit U3

The restricting comes as Daiichi Sankyo faces the loss of patent protection in the US for Benicar (olmesartan), a $2.4bn-a-year product used to treat high blood pressure.

Daiichi Sankyo cuts a swathe through US workforce

Japan's Daiichi Sankyo is planning to the slash the size of its US workforce as it contends with the loss of patent protection for top-selling drug Benicar. ... The company will need late-stage pipeline candidates to deliver if it is to ride out the

Daiichi Sankyo pays $39m in whistleblower case

several of its products, including high blood pressure treatment Benicar (olmesartan) and various combinations of the drug with other antihypertensive agents.

Takeda launches Azilva for blood pressure in Japan

Daiichi Sankyo's Benicar/Olmetec (olmesartan).

Result pages: 1 | 2 | 3 | 4 (Next 4)

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology

Featured jobs

Scientific Director / Editorial Team Leader: Great salary and benefits

Senior Medical Writer: Competitive Salary

Senior Medical Writer: Great salary and benefits

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Associate Medical Director: Highly Competitive

Director, Market Access / HEOR - North-West: Negotiable

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Medical Writers: Competitive Salary and Benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Medical Writers Required – Cheshire: DOE

Account Director: £48, 000 - £60, 000

Senior Account Director development role to Business Director, H...: Excellent package

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Account Manager: Negotiable

Events Manager – Med Comms – Surrey: Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Senior Systematic Review Analyst - Oxford: Negotiable

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Consultant Health Economics - London / Oxford: Negotiable

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health: For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...